Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Nephrotic Syndrome I : Introduction01:24

Nephrotic Syndrome I : Introduction

1.2K
Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of...
1.2K
Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

409
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
409
Proliferative Phase01:20

Proliferative Phase

1.9K
The proliferative phase typically occurs after menstruation and lasts between 6 to 13 days in a standard 28-day cycle. This phase involves the reconstruction of the endometrium, guided by estrogen produced by the developing ovarian follicle.
Notably, the stratum basale, the basal layer of the endometrium, including the basal parts of the uterine glands, remains unaffected by menstruation. Stem cells in this layer undergo mitosis, regenerating the stratum functionalis and thickening the...
1.9K
Graves Disease II: Pathophysiology01:24

Graves Disease II: Pathophysiology

26
Graves’ disease is an autoimmune disorder characterized by the production of thyroid-stimulating immunoglobulins (TSI) that activate TSH receptors, leading to excessive synthesis and release of thyroid hormones (T3 and T4) and resulting in hyperthyroidism.Among all causes of hyperthyroidism, Graves’ disease is the most common and can happen at any age, though it is more frequent in women. It produces a hypermetabolic state with features such as weight loss, tachycardia, tremor,...
26

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Establishing a core outcome measure for cancer in trials in kidney transplantation: a standardized outcomes in nephrology-kidney transplantation consensus workshop report.

Transplant international : official journal of the European Society for Organ Transplantation·2026
Same author

AKI After Hepatic Histotripsy.

Kidney international reports·2026
Same author

Phosphate Disorders in Cancer.

Kidney360·2026
Same author

Enteric and Controlled-Release Budesonide in IgA Nephropathy: Expanding Access While Refining Evidence.

Kidney international reports·2026
Same author

Post Kidney Transplant Thrombotic Microangiopathy: A Narrative Review of the Challenges and Opportunities.

Kidney360·2026
Same author

When the Podocyte Speaks First: Anti-Nephrin Associated Diffuse Podocytopathy Preceding Hodgkin's Lymphoma.

Kidney360·2026
Same journal

A Patient's Perspective on Arteriovenous Fistula Care and Far-Infrared Radiation Arteriovenous Fistula Therapy.

Clinical journal of the American Society of Nephrology : CJASN·2026
Same journal

A Beacon of Hope: Pegcetacoplan for Adolescents with C3 Glomerulopathy or Primary Immune Complex Membranoproliferative GN.

Clinical journal of the American Society of Nephrology : CJASN·2026
Same journal

Sequential Biomarker Testing in Kidney Transplant Surveillance: How Far Does One Step at a Time Take Us?

Clinical journal of the American Society of Nephrology : CJASN·2026
Same journal

The Predicting Risk of Cardiovascular Disease Event Equation Meets CKD.

Clinical journal of the American Society of Nephrology : CJASN·2026
Same journal

Muscle Cramp Rate, Severity and Burden in Maintenance Hemodialysis Patients: A Yearlong Multicenter Quality Improvement Initiative.

Clinical journal of the American Society of Nephrology : CJASN·2026
Same journal

From Risk Determinants to Clinical Action: Understanding and Implementing the Cardiovascular Kidney Metabolic Syndrome Framework.

Clinical journal of the American Society of Nephrology : CJASN·2026
See all related articles

Related Experiment Video

Updated: May 4, 2026

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
07:15

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Published on: August 23, 2024

1.1K

Update on membranoproliferative GN.

Naveed Masani1, Kenar D Jhaveri, Steven Fishbane

  • 1Division of Nephrology, Winthrop University Hospital, Mineola, New York, †Division of Kidney Diseases and Hypertension, Hofstra North Shore-Long Island Jewish School of Medicine, Great Neck, New York.

Clinical Journal of the American Society of Nephrology : CJASN
|January 11, 2014
PubMed
Summary
This summary is machine-generated.

Membranoproliferative glomerulonephritis (MPGN) is a kidney injury pattern. New classifications focus on immunofluorescence and complement system dysregulation for better diagnosis and treatment.

More Related Videos

Glomerular Outgrowth as an Ex Vivo Assay to Analyze Pathways Involved in Parietal Epithelial Cell Activation
06:39

Glomerular Outgrowth as an Ex Vivo Assay to Analyze Pathways Involved in Parietal Epithelial Cell Activation

Published on: August 19, 2020

5.0K
Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells
10:21

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells

Published on: February 21, 2018

9.3K

Related Experiment Videos

Last Updated: May 4, 2026

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
07:15

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Published on: August 23, 2024

1.1K
Glomerular Outgrowth as an Ex Vivo Assay to Analyze Pathways Involved in Parietal Epithelial Cell Activation
06:39

Glomerular Outgrowth as an Ex Vivo Assay to Analyze Pathways Involved in Parietal Epithelial Cell Activation

Published on: August 19, 2020

5.0K
Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells
10:21

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells

Published on: February 21, 2018

9.3K

Area of Science:

  • Nephrology
  • Pathology
  • Immunology

Background:

  • Membranoproliferative GN (MPGN) is identified by light microscopy.
  • Electron microscopy historically aided MPGN subclassification.
  • Recent research emphasizes immunofluorescence findings and pathobiology.

Purpose of the Study:

  • To propose a new classification scheme for MPGN based on immunofluorescence.
  • To highlight the role of complement system dysregulation in MPGN development.
  • To underscore the importance of understanding underlying mechanisms for evaluation and treatment.

Main Methods:

  • Review of historical classification methods (light and electron microscopy).
  • Analysis of recent advances in understanding MPGN pathobiology.
  • Proposed classification based on immunofluorescence findings.

Main Results:

  • A new classification scheme for MPGN is proposed.
  • Complement system dysregulation is identified as a major risk factor.
  • Immunofluorescence is central to the new classification.

Conclusions:

  • MPGN classification is evolving towards immunofluorescence-based criteria.
  • Understanding complement pathways is crucial for MPGN management.
  • Defining underlying mechanisms is key for effective MPGN evaluation and treatment.